Endothelial-targeted modification of ginseng-derived exosomes for IL-6 SiRNA delivery ameliorates hepatic ischemia-reperfusion injury
Quick Facts
- Publication title: Endothelial-targeted modification of ginseng-derived exosomes for IL-6 SiRNA delivery ameliorates hepatic ischemia-reperfusion injury
- Journal: J Nanobiotechnology
- Year: 2026
- DOI: 10.1186/s12951-025-03954-2
- PMID/PMCID: 41491215; PMC12781530
Research overview
This study developed endothelial-targeting VHPKQHR peptide (VHP)-modified ginseng-derived exosomes (G-Exos) loaded with IL-6 small interfering RNA (Si-IL6) (siRNA@VG-Exos) to mitigate liver IRI. Furthermore, they promoted the restoration of mitochondrial membrane potential, maintaining mitochondrial homeostasis.
Key findings
Liver ischemia-reperfusion injury (IRI) serves as a critical pathological basis for post-hepatectomy liver failure and graft dysfunction following liver transplantation.
Excessive inflammatory responses, oxidative stress, and cell death are key mechanisms underlying IRI.
The lack of multi-targeted therapies contributes to the current insufficiency in clinical IRI management.
This study developed endothelial-targeting VHPKQHR peptide (VHP)-modified ginseng-derived exosomes (G-Exos) loaded with IL-6 small interfering RNA (Si-IL6) (siRNA@VG-Exos) to mitigate liver IRI.
Echo Biotech Role
Echo Biotech contributed targeting-peptide/surface modification; the study also used or cited ExoBrooch™.
Related platforms: Echosome®, Research Reagents & Tools
Related services and capabilities: Targeting Peptide / Surface Modification, Research Reagent / Product Supply
Related products or reagents: ExoBrooch™ Targeting Peptide/Lipid Anchor Kit
References
Original publication: Endothelial-targeted modification of ginseng-derived exosomes for IL-6 SiRNA delivery ameliorates hepatic ischemia-reperfusion injury Journal of nanobiotechnology. 2026. DOI: 10.1186/s12951-025-03954-2. PMID/PMCID: 41491215; PMC12781530.